CN101181261A - 杨梅素在制备尿酸转运子urat1抑制药物中的应用 - Google Patents
杨梅素在制备尿酸转运子urat1抑制药物中的应用 Download PDFInfo
- Publication number
- CN101181261A CN101181261A CNA2007101901378A CN200710190137A CN101181261A CN 101181261 A CN101181261 A CN 101181261A CN A2007101901378 A CNA2007101901378 A CN A2007101901378A CN 200710190137 A CN200710190137 A CN 200710190137A CN 101181261 A CN101181261 A CN 101181261A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- urat1
- ampelopsin
- myricetin
- acid transporter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 28
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 229940116269 uric acid Drugs 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000000452 restraining effect Effects 0.000 title claims description 10
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 title abstract description 26
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 title description 21
- 235000007270 Gaultheria hispida Nutrition 0.000 title 1
- 235000009134 Myrica cerifera Nutrition 0.000 title 1
- 244000269152 Myrica pensylvanica Species 0.000 title 1
- 235000012851 Myrica pensylvanica Nutrition 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 229930003935 flavonoid Natural products 0.000 claims abstract description 3
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 3
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 3
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims description 84
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims description 42
- 241001465754 Metazoa Species 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 4
- 239000002775 capsule Substances 0.000 abstract description 3
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 2
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000000178 monomer Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 abstract 5
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 abstract 5
- 229940116852 myricetin Drugs 0.000 abstract 5
- 235000007743 myricetin Nutrition 0.000 abstract 5
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 229940109262 curcumin Drugs 0.000 abstract 1
- 235000012754 curcumin Nutrition 0.000 abstract 1
- 239000004148 curcumin Substances 0.000 abstract 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108010078530 urate transporter Proteins 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000011049 filling Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229950000193 oteracil Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 206010021131 Hypouricaemia Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003811 acetone extraction Methods 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 238000007445 Chromatographic isolation Methods 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000219433 Myrica Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 108091006745 SLC22A12 Proteins 0.000 description 1
- 101150078067 SLC22A12 gene Proteins 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
Abstract
本发明涉及黄酮类单体化合物杨梅素的新用途，具体是涉及杨梅素在制备尿酸转运子URAT1抑制药物中的应用。经动物试验结果表明：杨梅素对高尿酸血模型动物表达异常增高的尿酸转运子URAT1具有确切的抑制作用，而对正常动物的正常水平的尿酸转运子URAT1表达无显著抑制作用，具有很好的安全性，利用杨梅素配以相关的药用辅料，用常规的制剂方法可制成杨梅素口服液、胶囊剂、片剂、颗粒剂等尿酸转运子URAT1的抑制药物，可用于治疗与尿酸转运子URAT1异常高表达相关的疾病。
Description
技术领域：本发明涉及黄酮类单体化合物杨梅素的新用途，具体是涉及杨梅素在制备尿酸转运子URAT1抑制药物中的应用。
背景技术：尿酸排出减少或生成增加，可导致血液中尿酸浓度增高，直接或间接引起相关疾病。尿酸的***是一复杂过程，尿酸随血液循环流入肾小球时，游离型的尿酸将全部滤过；在近端肾小管约99％尿酸盐被重吸收(Diamond HS，MeiselAD.Postsecretory reabsorption of urate in man.Arthritis And Rheumatism，1975，18(6)：805-809.)。位于近曲小管的尿酸转运子(蛋白)URAT1参与尿酸重吸收过程，通过与阴离子的交换将尿酸盐由管腔转运入细胞。URAT1蛋白主要分布于肾皮质近曲小管上皮细胞向腔膜，是一个电中性的尿酸转运蛋白。URAT1基因由Enomoto等于2002年首先从人肾脏克隆出来，位于染色体11q13，由SLC22A12基因编码，由10个内含子9个外显子组成，拥有12个跨膜结构域，其cDNA全长2642bp，编码区1659bp，编码含555个氨基酸的蛋白质。原发性肾低尿酸血症(hypouricemia)病人的SLC22A12基因缺陷病例进一步证明人的URAT1(hURAT1)参与尿酸的重吸收(Atsushi Enomoto，Hiroaki Kimura，ArthitChairoungdua，Yasuhiro Shigeta，et al.Molecular identification of a renal urate-anionexchanger that regulates blood urate levels.Nature，2002，417(6887)：447-452)。
杨梅素结构式、分子式和美国化学文摘收录号(CAS No.)见下：
杨梅素可以由天然产物中分离得到，例如有文献报道从云南产矮杨梅(Myrica nanaCheva.1)鲜叶的80％丙酮浸提物中经葡聚糖凝胶和大孔吸附树脂柱层析反复分离提取杨梅素：矮杨梅鲜叶用80％丙酮浸提3次，浸提液减压回收丙酮后过滤，滤液用石油醚萃取，水层以大孔吸附树脂柱层析处理，水冲洗后用MeOH洗脱，回收甲醇，得褐黑色浸膏。将MeOH洗脱物溶于250mL水中，用SephadexHL-20柱层析分离纯化，分离得到杨梅素(周志宏.矮杨梅鲜叶的酚性化学成分研究.云南植物研究2000；22(2)：219-224.)。也有报道杨梅素由化学改构/合成得到(Hosny，Mohammed；Dhar，Kajari；Rosazza，John P.N.Hydroxylationsand Methylations of Quercetin，Fisetin，and Catechin by Streptomyces griseus.Journal of Natural Products(2001)，64(4)，462-465.)
杨梅素已见有多种生理和药理活性的报道，包括血小板活化因子(PAF)的拮抗作用、降血糖作用、抗氧化作用、保肝护肝作用、解轻乙醇中毒等(唐霖，张莉静，王明谦.中成药2006；28(1)：121-122)。但杨梅素单体用于制备针对电中性尿酸转运子URAT1的抑制药物，则未见报道。
发明内容：本发明的目的是提供单体化合物杨梅素的新用途，具体是杨梅素在制备尿酸转运子URAT1抑制药物中的应用。
本发明的技术解决方案之一是：提供单体化合物杨梅素在制备尿酸转运子URAT1抑制药物的新用途。该新用途包括了以本发明所述的杨梅素，配以本领域的技术人员所熟知的药用辅料(赋形剂、助溶剂、控释剂等)，制成本领域的技术人员所熟知的剂型(包括口服液、注射剂、胶囊剂、片剂、颗粒剂、微囊剂等)，用于制备尿酸转运子URAT1抑制药物。
本发明的优点是，提供了对尿酸转运子URAT1具有确切抑制调节作用的杨梅素，用于制备尿酸转运子URAT1抑制药物，可用于治疗与尿酸转运子URAT1异常高表达相关疾病。与针对痛风或者高尿酸血病症的发明比较，本发明提供的单体化合物杨梅素制备尿酸转运子URAT1抑制药物新用途具有3个明显的进步和优点：1、有效成分确切(单体化合物)；2、作用靶点明确(尿酸***过程中重吸收作用的尿酸转运子URAT1)；3、调节作用明确(抑制调节)。
本发明利用高尿酸血动物模型在基因转录水平和蛋白表达水平上科学地评价并确定了单体化合物杨梅素对尿酸转运子URAT1的抑制调控作用。
本发明所涉及的单体化合物杨梅素对模型动物表达异常增高的尿酸转运子URAT1具有确切的抑制作用；而对正常动物的正常水平的尿酸转运子表达无显著抑制作用，具有很好的安全性。
为了更好的理解本发明的实质，下面将用单体化合物杨梅素的的药理实验及结果来说明其在制备尿酸转运子URAT1抑制药物中的应用。
具体实施方式：以下实施例仅作为进一步阐述发明之用，不能用来限制本发明。
实施例1：单体化合物杨梅素对尿酸转运子URAT1的抑制调节作用
实验动物：昆明种小鼠，15-20克，雄性
药物配制：杨梅素均匀分散于生理盐水中，用于灌胃给药，给药剂量为20mg/kg
实验材料：Trizol Reagment(Invigen)，氯仿，异丙醇，无水乙醇，DEPC，M-MLV反转录酶，PCR试剂盒，RIPA裂解液等
实验仪器：高速冷冻离心机，高速匀浆机，Bio-rad垂直电泳槽，MBI-PCR仪、水平电泳槽等
实验模型：小鼠高尿酸血症模型。
实验方法：
1、模型的建立：动物适应环境1周后，灌胃给予氧嗪酸钾盐250mg/kg；对照给予等体积生理盐水，造模周期10天。
2、给药：造模期间同时给药，在给予氧嗪酸钾盐造模/生理盐水对照1h后，灌胃给予单体化合物杨梅素20mg/kg；对照给予生理盐水。
3、小鼠处死及组织的保存：小鼠于灌胃给予杨梅素/生理盐水后1小时处死，冰台上分离肾脏组织，肾组织经液氮冷冻后保存于-80℃。
4、蛋白质印迹法(Western-blotting)：取组织约100mg加入1ml的RIPA裂解液匀浆提取，12000g4℃离心15分钟，得肾脏组织总蛋白提取液，Bradford法测蛋白浓度，稀释蛋白样品至终浓度为5ug/ul。混合上样缓冲液变性上样，SDS-PAGE凝胶电泳后PVDF转膜，封闭液封闭1小时后加入mURAT1抗体(根据NCBI数据库mURAT1蛋白序列制备，使用浓度1∶4000)4℃孵育过夜，二抗(1∶4000)室温摇床孵育1小时，HRP-ECL发光，暗室曝光显影。胶片扫描后对图片进行灰度分析。
5、逆转录聚合酶链反应(RT-PCR)：提取小鼠肾脏总RNA，逆转录得到cDNA模板，根据NCBI数据库的mURAT1基因设计引物，进行mURAT1目的基因扩增。扩增产物经琼脂糖凝胶电泳后UV成像，对图片进行灰度分析。
实验结果：
a.蛋白质印迹法Western-Blotting
| Groupn＝5 | 空白+生理盐水 | 空白+杨梅素 | 模型+生理盐水 | 模型+杨梅素 |
| 灰度值 | 36.7±8.1 | 38.6±9.3 | 56.0±11.3++ | 40.4±10.0* |
++＜0.01与空白+生理盐水组比较 *P＜0.05与模型+生理盐水组比较连续10天灌胃给予氧嗪酸钾盐250mg/kg造模造成小鼠肾组织中URAT1蛋白高水平表达，灰度值达到56.0，显著高于空白对照36.7。灌胃给予20mg/kg的单体化合物杨梅素可显著抑制模型小鼠肾组织中URAT1蛋白的高水平表达，灰度值为40.4，接近空白对照水平。说明单体化合物杨梅素显著抑制模型动物异常增高的尿酸转运子URAT1蛋白表达。灌胃给予单体化合物杨梅素对空白小鼠肾组织中URAT1蛋白表达水平无显著影响，说明单体化合物杨梅素对小鼠肾组织正常水平的URAT1蛋白无显著抑制作用，具有较好的安全性。
b.逆转录聚合酶链反应RT-PCR
| Groupn＝5 | 空白+生理盐水 | 空白+杨梅素 | 模型+生理盐水 | 模型+杨梅素 |
| 灰度值 | 29.7±7.4 | 30.2±10.2 | 66.1±16.8++ | 30.9±13.5** |
++P＜0.01与空白+生理盐水组比较 **P＜0.01 与模型+生理盐水组比较连续10天灌胃给予氧嗪酸钾盐250mg/kg造模造成小鼠肾组织中URAT1 mRNA高水平表达，灰度值达到66.1，显著高于空白对照29.7。灌胃给予20mg/kg的单体化合物杨梅素可显著抑制模型小鼠肾组织中URAT1 mRNA的高水平表达，灰度值为30.9，接近空白对照水平。说明单体化合物杨梅素可在转录水平上抑制异常增高的尿酸转运子URAT1 mRNA表达。灌胃给予单体化合物杨梅素的空白小鼠肾组织中URAT1 mRNA表达水平为30.2，相对于空白对照组无显著变化，说明单体化合物杨梅素对小鼠肾组织正常水平的URAT1 mRNA无显著抑制作用，具有较好的安全性。
实施例2：
将单体化合物杨梅素按照常规制剂方法，加入水及适量增溶剂(聚乙二醇400)溶解，分装，灭菌，制备成规格为10mg/ml的杨梅素口服液；
将单体化合物杨梅素按照常规制剂方法，软胶囊材质选用明胶和山梨醇，制备成规格为10mg/粒的杨梅素胶囊；
将单体化合物杨梅素按照常规制剂方法，加入赋形剂环糊精，混合均匀，制粒，压片，制备成规格为10mg/片的杨梅素片剂
Claims (1)
1.黄酮类单体化合物杨梅素在制备尿酸转运子URAT1抑制药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101901378A CN101181261A (zh) | 2007-11-15 | 2007-11-15 | 杨梅素在制备尿酸转运子urat1抑制药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101901378A CN101181261A (zh) | 2007-11-15 | 2007-11-15 | 杨梅素在制备尿酸转运子urat1抑制药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101181261A true CN101181261A (zh) | 2008-05-21 |
Family
ID=39446775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101901378A Pending CN101181261A (zh) | 2007-11-15 | 2007-11-15 | 杨梅素在制备尿酸转运子urat1抑制药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101181261A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655540A (zh) * | 2012-09-26 | 2014-03-26 | 四川大学华西医院 | 杨梅素晶体化合物用于神经抑制剂的药物的应用 |
| WO2020031961A1 (ja) * | 2018-08-10 | 2020-02-13 | サントリーホールディングス株式会社 | 尿酸排出促進用組成物、ｕｒａｔ１阻害用組成物及び血中尿酸値低下用組成物 |
| CN114028584A (zh) * | 2021-11-18 | 2022-02-11 | 辽宁万嘉医药科技有限公司 | 一种降尿酸的多酚多元环糊精包合物及其制备方法 |
| CN116210900A (zh) * | 2022-12-29 | 2023-06-06 | 抱朴生命科技(广州)有限公司 | 一种调节黄嘌呤氧化酶活性的植物多酚缓释组合物及其精准营养物和制备方法 |
-
2007
- 2007-11-15 CN CNA2007101901378A patent/CN101181261A/zh active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655540A (zh) * | 2012-09-26 | 2014-03-26 | 四川大学华西医院 | 杨梅素晶体化合物用于神经抑制剂的药物的应用 |
| CN103655540B (zh) * | 2012-09-26 | 2015-12-02 | 四川大学华西医院 | 杨梅素晶体化合物用于神经抑制剂的药物的应用 |
| WO2020031961A1 (ja) * | 2018-08-10 | 2020-02-13 | サントリーホールディングス株式会社 | 尿酸排出促進用組成物、ｕｒａｔ１阻害用組成物及び血中尿酸値低下用組成物 |
| CN112566514A (zh) * | 2018-08-10 | 2021-03-26 | 三得利控股株式会社 | 尿酸排出促进用组合物、urat1抑制用组合物及血液中尿酸值降低用组合物 |
| JPWO2020031961A1 (ja) * | 2018-08-10 | 2021-08-12 | サントリーホールディングス株式会社 | 尿酸排出促進用組成物、ｕｒａｔ１阻害用組成物及び血中尿酸値低下用組成物 |
| JP7307073B2 (ja) | 2018-08-10 | 2023-07-11 | サントリーホールディングス株式会社 | 尿酸排出促進用組成物、ｕｒａｔ１阻害用組成物及び血中尿酸値低下用組成物 |
| CN114028584A (zh) * | 2021-11-18 | 2022-02-11 | 辽宁万嘉医药科技有限公司 | 一种降尿酸的多酚多元环糊精包合物及其制备方法 |
| CN114028584B (zh) * | 2021-11-18 | 2023-09-05 | 辽宁万嘉医药科技有限公司 | 一种降尿酸的多酚多元环糊精包合物及其制备方法 |
| CN116210900A (zh) * | 2022-12-29 | 2023-06-06 | 抱朴生命科技(广州)有限公司 | 一种调节黄嘌呤氧化酶活性的植物多酚缓释组合物及其精准营养物和制备方法 |
| CN116210900B (zh) * | 2022-12-29 | 2024-01-30 | 抱朴生命科技(广州)有限公司 | 一种调节黄嘌呤氧化酶活性的植物多酚缓释组合物及其精准营养物和制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
| CN101181345B (zh) | 槐米黄酮提取物在制备尿酸转运子urat1抑制药物中的应用 | |
| CN102239149A (zh) | 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法 | |
| AU2014360040B2 (en) | Desmodium styracifolium (Osb.) Merr. flavonoids capsule, method of preparing same, and application thereof | |
| CN100577677C (zh) | 络石藤总木脂素提取物,提取方法及该提取物和其中有效成分的医药用途 | |
| CN103327992A (zh) | 用于预防或治疗炎性疾病的包含络石藤提取物和牡丹皮提取物的药物组合物以及制备该药物组合物的方法 | |
| US20160151435A1 (en) | Pharmaceutical composition adjuvant to chemotherapy drugs and applications thereof | |
| CN106916161A (zh) | 一种异戊烯基黄酮及其在制备治疗炎症性疾病药物中的用途 | |
| JP2020532501A (ja) | 糸球体の足細胞傷害型腎臓病を予防又は治療する薬物の調製へのアクテオシドの使用 | |
| CN101181261A (zh) | 杨梅素在制备尿酸转运子urat1抑制药物中的应用 | |
| JP2021038235A (ja) | 癌を治療するための方法および物質 | |
| CN101781355B (zh) | 柠檬苦素的制备方法及组合物和其应用 | |
| CN101181287A (zh) | 葛根素在制备尿酸转运子urat1抑制药物中的应用 | |
| CN108434130A (zh) | 氯硝柳胺乙醇胺盐及其药物组合物的应用 | |
| CN100571692C (zh) | 姜黄素在制备尿酸转运子urat1抑制药物中的应用 | |
| TWI610676B (zh) | 神經細胞死抑制劑、抗阿茲海默症劑、抗腦機能減退劑、具有抗阿茲海默症作用或抗腦機能減退作用的醫藥品及神經細胞死抑制劑的製造方法 | |
| CN101181262A (zh) | 香豆素单体化合物在制备尿酸转运子urat1抑制药物中的应用 | |
| Shui et al. | Jieduquyuziyin prescription suppresses IL-17 production and Th17 activity in MRL/lpr mice by inhibiting expression of Ca 2+/calmodulin-dependent protein kinase-4 | |
| CN105560302B (zh) | 老鹳草水提物在制备抗血管生成类药物中的应用 | |
| US20200222485A1 (en) | Medicinal ambrosia plant extracts | |
| CN112898131A (zh) | ***二酚的提取工艺及***二酚或***提取物在制备预防或者治疗bph的药物中的应用 | |
| CN114588187B (zh) | 一种治疗白内障的中药总黄酮提取物及其组合物、制备方法和医药用途 | |
| RU2339390C1 (ru) | Способ получения водных извлечений и полифенолов чаги, обладающих антиоксидантной активностью | |
| EP3053575B1 (en) | Agent for preventing or ameliorating renal dysfunction | |
| CN101502527A (zh) | 桑皮苷在制备抑制尿酸重吸收转运子药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080521 |